Neusentis, Inc.

Neusentis, Inc.

Neusentis, Inc.

Overview
Date Founded

1992

Headquarters

4222 Emperor Boulevard,Suite 350,Durham, NC 27703

Type of Company

Private

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC.

Executives & Employees

Head of Molecular & Cellular Biology

Vice President & Site Head of Pain, Sensory Disorders & Regenerative Medicine Research

Senior Director, in Vivo Physiology Group

Vice President-New Product Development

Board of Directors

Venture Partner at SV Health Investors LLP

Adjunct Professor of Business Management & Marketing at The University of North Carolina at Wilmington

Director at Neusentis, Inc.

Paths to Neusentis, Inc.
Potential Connections via
Relationship Science
You
Neusentis, Inc.
Recent Transactions
Details Hidden

Pfizer, Inc. purchases Neusentis, Inc. from Merlin Biomed Private Equity Advisors LLC, New Leaf Venture Partners LLC

Details Hidden

Neusentis, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onNeusentis, Inc. issued USD Common Stock

Escrow Agent

Advised onPfizer, Inc. purchases Neusentis, Inc. from Merlin Biomed Private Equity Advisors LLC, New Leaf Venture Partners LLC

Underwriter

Advised onNeusentis, Inc. issued USD Common Stock

Co-Chair, Life Sciences Group

Advised onNeusentis, Inc. issued USD Common Stock

Legal Advisor

Advised onNeusentis, Inc. issued USD Common Stock

Co-Founder

Advised onNeusentis, Inc. issued USD Common Stock

Non-Profit Donations & Grants
Investors
Details Hidden

Chief Executive Officer at Prognomix, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Neusentis, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Neusentis, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Neusentis, Inc..